The HDAC inhibitor vorinostat diminishes the in vitro metastatic behavior of osteosarcoma cells

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Mu, Xiaodong ^a   Brynien, Daniel ^a   Weiss, Kurt R ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE DEHYDROGENASE ISOENZYME 1; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1; UNCLASSIFIED DRUG; VORINOSTAT; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; ISOENZYME; PEROXISOME-PROLIFERATOR-ACTIVATED RECEPTOR-GAMMA COACTIVATOR-1; RETINAL DEHYDROGENASE; TRANSCRIPTION FACTOR;

ANIMAL CELL; ARTICLE; CELL COUNT; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CELL STRUCTURE; CONTROLLED STUDY; DOWN REGULATION; ENERGY METABOLISM; GENE EXPRESSION; IN VITRO STUDY; METASTASIS POTENTIAL; MOUSE; NONHUMAN; OSTEOSARCOMA; OSTEOSARCOMA CELL; PHENOTYPE; PROTEIN EXPRESSION; ANIMAL; BONE NEOPLASMS; CELL MOTION; DNA METHYLATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; METABOLISM; NEOPLASM METASTASIS; PATHOLOGY; TUMOR CELL LINE;

MURINAE;

ANIMALS; BONE NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DNA METHYLATION; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE INHIBITORS; HYDROXAMIC ACIDS; ISOENZYMES; MICE; NEOPLASM METASTASIS; OSTEOSARCOMA; RETINAL DEHYDROGENASE; TRANSCRIPTION FACTORS;

EID: 84924322563     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/290368     Document Type: Article

References (25)

1. G. Bacci, A. Briccoli, M. Mercuri et al., "Osteosarcoma of the extremities with synchronous lung metastases: long-term results in 44 patients treated with neoadjuvant chemotherapy," Journal of Chemotherapy, vol. 10, no. 1, pp. 69-76, 1998.
2. G. Bacci, S. Ferrari, M. Mercuri et al., "Predictive factors for local recurrence in osteosarcoma 540 Patients with extremity tumors followed for minimum 2.5 years after neoadjuvant chemotherapy," Acta Orthopaedica Scandinavica, vol. 69, no. 3, pp. 230-236, 1998.
3. G. Bacci, S. Ferrari,M.Mercuri et al., "Neoadjuvant chemotherapy for extremity osteosarcoma: preliminary results of the Rizzoli's 4th study," Acta Oncologica, vol. 37, no. 1, pp. 41-48, 1998.
4. S. S. Bielack, B. Kempf-Bielack, G. Delling et al., "Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols," Journal of Clinical Oncology, vol. 20, no. 3, pp. 776-790, 2002.
5. L. Kager, U. Pötschger, and S. Bielack, "Review of mifamurtide in the treatment of patients with osteosarcoma," Therapeutics and Clinical Risk Management, vol. 6, pp. 279-286, 2010.
6. L. Kager, A. Zoubek,M.Dominkus et al., "Osteosarcoma invery young children: experience of the Cooperative Osteosarcoma Study Group," Cancer, vol. 116, no. 22, pp. 5316-5324, 2010.
7. N. Marina, M. Gebhardt, L. Teot, and R. Gorlick, "Biology and therapeutic advances for pediatric osteosarcoma," Oncologist, vol. 9, no. 4, pp. 422-441, 2004.
8. I. Bortolomai, S. Canevari, I. Facetti et al., "Tumor initiating cells: development and critical characterization of a model derived from the A431 carcinoma cell line forming spheres in suspension," Cell Cycle, vol. 9, no. 6, pp. 1194-1206, 2010.
9. C. Khanna, J.Khan, P. Nguyen et al., "Metastasis-associated differences in gene expression in amurinemodel of osteosarcoma," Cancer Research, vol. 61, no. 9, pp. 3750-3759, 2001.
10. C. Khanna, J. Prehn, C. Yeung, J. Caylor, M. Tsokos, and L. Helman, "An orthotopic model of murine osteosarcoma with clonally related variants differing in pulmonary metastatic potential," Clinical and Experimental Metastasis, vol. 18, no. 3, pp. 261-271, 2000.
11. K. R. Weiss, G. M. Cooper, J. A. Jadlowiec, R. L. McGough III, and J. Huard, "VEGF and BMP expression in mouse osteosarcoma cells," Clinical Orthopaedics and Related Research, vol. 450, pp. 111-117, 2006.
12. N. Greco, T. Schott, X.Mu et al., "ALDH activity correlates with metastatic potential in primary sarcomas of bone," Journal of CancerTherapy, vol. 5, no. 4, pp. 331-338, 2014.
13. X. Mu, C. Isaac, N. Greco, J. Huard, and K. Weiss, "Notch signaling is associated with ALDH activity and an aggressive metastatic phenotype in murine osteosarcoma cells," Frontiers in Oncology, vol. 3, article 143, 2013.
14. X. Mu, C. Isaac, T. Schott, J. Huard, and K. Weiss, "Rapamycin inhibits ALDH activity, resistance to oxidative stress, and metastatic potential in murine osteosarcoma cells," Sarcoma, vol. 2013, Article ID 480713, 11 pages, 2013.
15. X.Mu, B. Sultankulov, R. Agarwal et al., "Chick embryo extract demethylates tumor suppressor genes in osteosarcoma cells," Clinical Orthopaedics and Related Research, vol. 472, no. 3, pp. 865-873, 2014.
16. S. Ropero and M. Esteller, "The role of histone deacetylases (HDACs) in human cancer," Molecular Oncology, vol. 1, no. 1, pp. 19-25, 2007.
17. P. E. Burger, R. Gupta, X. Xiong et al., "High aldehyde dehydrogenase activity: a novel functional marker of murine prostate stem/progenitor cells," Stem Cells, vol. 27, no. 9, pp. 2220-2228, 2009.
18. E. Charafe-Jauffret, C. Ginestier, F. Iovino et al., "Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer," Clinical Cancer Research, vol. 16, no. 1, pp. 45-55, 2010.
19. M. R. Clay, M. Tabor, J. H. Owen et al., "Single-marker identification of head and neck squamous cell carcinoma cancer stem cells with aldehyde dehydrogenase,"Head & Neck, vol. 32, no. 9, pp. 1195-1201, 2010.
20. A. K. Croker, D. Goodale, J. Chu et al., "High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability," Journal of Cellular and Molecular Medicine, vol. 13, no. 8, pp. 2236-2252, 2009.
21. S.Deng, X. Yang,H.Lassus et al., "Distinct expressionlevels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers," PLoS ONE, vol. 5, no. 4, Article ID e10277, 2010.
22. C. Ginestier, M. H. Hur, E. Charafe-Jauffret et al., "ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome," Cell Stem Cell, vol. 1, no. 5, pp. 555-567, 2007.
23. T. Reya, S. J. Morrison, M. F. Clarke, and I. L.Weissman, "Stem cells, cancer, and cancer stem cells," Nature, vol. 414, no. 6859, pp. 105-111, 2001.
24. L. A. Lambert, N. Qiao, K. K. Hunt et al., "Autophagy: a novel mechanism of synergistic cytotoxicity between doxorubicin and roscovitine in a sarcomamodel," Cancer Research, vol. 68,no. 19, pp. 7966-7974, 2008.
25. F. Sotgia, D. Whitaker-Menezes, U. E. Martinez-Outschoorn et al., "Mitochondria 'fuel' breast cancer metabolism: fifteen markers of mitochondrial biogenesis label epithelial cancer cells, but are excluded from adjacent stromal cells," Cell Cycle, vol. 11, no. 23, pp. 4390-4401, 2012.